On April 4, 2022, Wuhan Healthgen Biotechnology Corp. closed the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.95 CNY | +0.57% | +5.32% | -14.74% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.74% | 2.54B | |
+6.52% | 71.18B | |
+12.83% | 9.23B | |
-11.55% | 5B | |
+48.05% | 4.46B | |
+5.09% | 3.95B | |
+20.00% | 2.44B | |
-24.89% | 2.36B | |
+21.45% | 2.18B | |
+7.64% | 1.67B |
- Stock Market
- Equities
- 300558 Stock
- News Betta Pharmaceuticals Co., Ltd.
- Wuhan Healthgen Biotechnology Corp. announced that it has received CNY 464.999997 million in funding from Hangzhou Beijia Investment Management Co., Ltd., Betta Pharmaceuticals Co., Ltd.